Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06195228 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

StatusRecruiting
PhasePhase 4
Started2020-01-01
View on ClinicalTrials.gov ↗

Amendment history

2025-08-09
Study Status, Sponsor/Collaborators, Study Description, Study Design, Eligibility, Contacts/Locations v3
Primary completion date2026-04-30→2026-12-31
Completion date2027-04-30→2028-12-31
Enrollment target200→800
Study sites3→8
Eligibility criteria-31 characters
Inclusion Criteria: Patients volunteered to participate in this study and signed informed consent; Age:Each ≥center 18can yearsbe oldenrolled in patients who meet the age of their own practice range, maleregardless orof femalegender ; Histologically diagnosed locally advanced or recurrent / m [...] s one of the following requirements: Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC); Differentiated thyroid carcinoma not suitable for iodine therapy; Medullary thyroid carcinoma (MTC); High-grade or poorly differentiated thyroid cancer; Anaplastic (PDTC) or anaplastic thyroid cancer (ATC) [...]
Study description+26 characters
see:Arms and Interventions
Collaborators2 to 23 entries
InnerPeking MongoliaUnion Medical College Hospital Henan Cancer Hospital Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Zhejiang Cancer Hospital The Affiliated ToHospital of Inner Mongolia Medical University Ruijin Hospital Fujian Cancer Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Shanghai 6th People's Hospital Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Shanghai 10th People's Hospital Shanghai General Hospital, Shanghai Jiao Tong University School [...]
2024-04-29
Study Status, Sponsor/Collaborators, Contacts/Locations v2
Study sites1→3
Collaborators+110 characters
Inner Mongolia Cancer Hospital Affiliated To Inner Mongolia Medical University Shanxi Province Cancer Hospital
2024-01-15
Study Status, Arms and Interventions v1
InterventionsOther Targets: precise treatment based on the target (Drug), anlotinib or anlotinib plus anti-PD-1 antibody (Drug), dabrafenib plus…→Other Targets: precise treatment based on the target (Drug), anlotinib or anlotinib plus anti-PD-1 antibody (Drug), dabrafenib plus…
2023-12-23
Original filing
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
Trial Details
NCT Number NCT06195228
Lead Sponsor Fudan University
Collaborators: Peking Union Medical College Hospital, Shanxi Province Cancer Hospital, Henan Cancer Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Zhejiang Cancer Hospital, The Affiliated Hospital of Inner Mongolia Medical University, Ruijin Hospital, Fujian Cancer Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Shanghai 6th People's Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 10th People's Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Changhai Hospital, Tianjin Medical University Cancer Institute and Hospital, Jiangsu Cancer Institute & Hospital, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hunan Provincial People's Hospital, Dalian Friendship Hospital Affiliated to Dalian Medical University, The Third Affiliated Hospital of Soochow University, Sun Yat-sen University, Liaoning Cancer Hospital & Institute, Sir Run Run Shaw Hospital
Conditions Advanced Thyroid Cancer Patients Who Received Target Therapy
Enrollment 800 participants
Start Date 2020-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-14